Article
Johnson & Johnson spotlights safety edge after Stelara's near miss against Humira in Crohn's
Rating:
0.0
Views:
117
Likes:
1
Library:
1
Johnson & Johnson's immunology med Stelara went head-to-head against AbbVie's stalwart Humira in Crohn's disease, looking for bragging rights to help it compete in that market. It didn't work—at least not in the way J&J might have hoped.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value